Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Vaccines for All People to Be Delivered to Local Govts by October-End: Kono
June 30, 2021
- MHLW to Start Study on US, European Schemes on ADR Evaluation
June 29, 2021
- MHLW Extends Maximum Biz Suspension Period to 180 Days in All Prefectures
June 29, 2021
- Japan Issues Guidelines on Drug Delivery by Drones; Operation Plan, Quality Assurance Required
June 28, 2021
- Japan Allots 33 Million Moderna Shots to Companies, 17 Million to Local Govts: Minister
June 28, 2021
- PMDA Reviewing New Safety Risk for Evenity, 13 Other APIs
June 28, 2021
- MHLW Announces Recommendation for Cannabis Drug Debate
June 28, 2021
- Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
June 24, 2021
- Japan to Stop Accepting Requests for Moderna Vaccines for Workplace Inoculations
June 24, 2021
- Panel OKs PI Study for Temcell Use in Refractory Skin Ulcer
June 24, 2021
- PMDA COVID-19 Vaccine Consultation Draws 129 Inquiries in 8 Months
June 24, 2021
- Chuikyo OKs Drug Price Survey Plan for FY2022 Revision
June 24, 2021
- Drug Pricing Rules to Be Applied to Oncolytic Virus Delytact: Chuikyo
June 24, 2021
- MHLW Panel Roughly OKs Scheme for Generic Makers to Join Revlimid Risk Management Program
June 23, 2021
- Orphan Status Granted to Unitalc, TransCon PTH
June 23, 2021
- Japan OKs 2021 Fiscal Policy Blueprint, Vows Transparency in Drug Pricing
June 21, 2021
- MHLW to Prioritize Application Reviews for COVID-19 Products, Expecting Rush of Filings
June 21, 2021
- MHLW Aims to Set Up Evaluation Index, Sakigake System for SaMD by March
June 18, 2021
- Cymbalta Generics Priced at 33.2% of Originator Tags: June Listing
June 18, 2021
- 9 Drugs Face Generic Entries, AGx Debuts for 2 Brands: June Listing
June 17, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…